PHTMAIN PHT Futures(OCT4)
- 14.50
- 0.000.00%
PHT Futures(OCT4) News
Ping An Health (01833) turned losses into profits in the first half of the year. CITIC Lyon is bullish on the recovery of the F-end business and maintains an 'outperform' rating.
Ping An Good Doctor (1833.HK): 24H1 Turns Losses into Profits: Comprehensive Layout of the “Healthcare” Sector
Ping An Good Doctor (1833.HK): 1H24 surpassed expectations and achieved profit in the short term, focus on when revenue growth resumed and room for profit margin improvement
DBS upgraded PA Good Doctor's rating to 'synchronized with the market', according to reports.
Ping An Good Doctor (01833.HK): Continue to deepen collaboration with the Group to deepen the healthcare and pension ecosystem
Good Doctor Ping An (1833.HK): Focus on new developments after strategic transformation
Dahua Jixian: Strategic business is expected to achieve double-digit growth and maintain Ping An Good Doctor (01833) “buy” rating
Ping An Good Doctor (01833)'s front-end and back-end strategy progressed smoothly, and Daimo raised the target price to HK$21
UBS: Strategy 2.0 has achieved results and a target price of HK$20 for Safe Doctor (01833)
Ping An Good Doctor (1833.HK): Business restructuring has basically completed gross margin and cost reductions to drive loss reduction
Ping An Good Doctor (01833.HK) Commentary on important matters: the implementation of the new strategy awaits results
Many brokerage firms such as Omo and Goldman Sachs jointly believe that the highest target price for Safety and Health (01833) is HK$24
Good Doctor Ping An (01833.HK): Group Collaboration Helps Develop Profit and Loss Balance Is Dawning
Safe Doctor (1833.HK): Combining Strong Forces to Enhance Competitiveness and Accelerate Implementation of a New Strategy
Ping An Good Doctor (01833.HK) 2023 Interim Report Review: Strategy 2.0 Continues to Deepen, Reduce Costs, and Increase Efficiency Results Show
Ping An Good Doctor (01833.HK) 2023 Interim Report Review: Various businesses are progressing steadily and performance is in line with expectations
Good Doctor Ping An (01833.HK): F/B users steadily increased and losses continued to narrow
Bank Rating｜Citibank: Maintaining Safe Good Doctor's “Buy” Rating Target Price Lowered to HK$35
Good Doctor Ping An (01833.HK): Business structure continues to adjust, gross margin level increases steadily
Good Doctor Ping An (1833.HK): Quimu's net loss narrowed by 47.1%, and 23H2 is expected to enter a long-term growth phase